Bodnar Lisa M, Platt Robert W, Simhan Hyagriv N
Department of Epidemiology, Graduate School of Public Health, and the Department of Obstetrics, Gynecology, and Reproductive Sciences, School of Medicine, University of Pittsburgh, and Magee-Womens Research Institute, Pittsburgh, Pennsylvania; and the Departments of Pediatrics and Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.
Obstet Gynecol. 2015 Feb;125(2):439-447. doi: 10.1097/AOG.0000000000000621.
To estimate the association between maternal 25-hydroxyvitamin D concentrations and risk of preterm birth subtypes.
We performed a case-cohort study using data and banked samples from patients at a teaching hospital in Pittsburgh, Pennsylvania. Eligible participants were women with a prenatal aneuploidy screening serum sample at or before 20 weeks of gestation who subsequently delivered a singleton, liveborn neonate. Of the 12,861 eligible women, we selected 2,327 at random as well as all remaining preterm birth cases for a total of 1,126 cases. Serum 25-hydroxyvitamin D was measured using liquid chromatography-tandem mass spectrometry. Multivariable log-binomial regression models were used to estimate associations between maternal vitamin D status and preterm birth at 37 weeks of gestation (separately by spontaneous or indicated) and preterm birth at less than 34 weeks of gestation.
The incidence of preterm birth at less than 37 weeks of gestation was 8.6% overall and 11.3%, 8.6%, and 7.3% among mothers with serum 25-hydroxyvitamin D less than 50, 50-74.9, and 75 nmol/L or greater, respectively (P<.01). After adjustment for maternal race and ethnicity, prepregnancy body mass index, season, smoking, and other confounders, the risk of preterm birth at less than 37 weeks of gestation significantly decreased as 25-hydroxyvitamin D increased to approximately 90 nmol/L and then plateaued (test of nonlinearity P<.01). Results were similar when limiting to cases that were medically indicated or occurred spontaneously and cases occurring at less than 34 weeks of gestation.
Our data support a protective association maternal vitamin D sufficiency and preterm birth that combined with extant epidemiologic data may provide justification for a randomized clinical trial of maternal vitamin D replacement or supplementation to prevent preterm birth.
评估母亲25-羟基维生素D浓度与早产亚型风险之间的关联。
我们利用宾夕法尼亚州匹兹堡一家教学医院患者的数据和储存样本进行了一项病例队列研究。符合条件的参与者为妊娠20周及以前进行过产前非整倍体筛查血清样本检测、随后分娩出单胎活产新生儿的女性。在12861名符合条件的女性中,我们随机选取了2327名,以及所有其余的早产病例,共1126例。采用液相色谱-串联质谱法测定血清25-羟基维生素D。使用多变量对数二项回归模型评估母亲维生素D状态与妊娠37周时早产(分别按自然早产或医源性早产)以及妊娠不足34周时早产之间的关联。
妊娠不足37周时早产的总体发生率为8.6%,血清25-羟基维生素D低于50、50 - 74.9以及75 nmol/L及以上的母亲中早产发生率分别为11.3%、8.6%和7.3%(P<0.01)。在对母亲种族和族裔、孕前体重指数、季节、吸烟及其他混杂因素进行调整后,随着25-羟基维生素D增加至约90 nmol/L,妊娠不足37周时早产风险显著降低,之后趋于平稳(非线性检验P<0.01)。当仅限于医源性早产或自然早产病例以及妊娠不足34周时发生的病例时,结果相似。
我们的数据支持母亲维生素D充足与早产之间存在保护性关联,结合现有流行病学数据,这可能为进行母亲维生素D替代或补充以预防早产的随机临床试验提供依据。